OTR3
OTR3 is a biotechnology company founded by Professors Denis Barritault and Jean-Pierre Caruelle† from the University of Paris-East Créteil in 2000, laureates of the French national competition for the creation of the best innovative company. Known for their pioneering work on growth factors – the discovery of FGF, HARP/PTN – they invented the RGTA® Technology (ReGeneraTing Agents), a new therapeutic class in regenerative medicine.
OTR3
Social Links:
Industry:
Biotechnology
Founded:
2000-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.otr3.com
Total Employee:
11+
Status:
Active
Contact:
+33 (0)1 83 64 23 00
Email Addresses:
[email protected]
Total Funding:
3.4 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Domain Not Resolving Sitelinks Search Box IPv6 Yoast WordPress SEO Plugin Yoast SEO Premium
Similar Organizations
Idogen
Idogen is a biotechnology company.
Immunicom
Immunicom is a biotechnology company.
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Microstech
microsTECH is a biotechnology company.
Neomorph
Neomorph is a biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Employees Featured
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - OTR3
Official Site Inspections
http://www.otr3.com
- Host name: cluster003.ovh.net
- IP address: 213.186.33.4
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "OTR3"
OTR3 - Société de thérapie matricielle en médecine …
OTR3 est une entreprise de biotechnologie avec un focus important sur le développement de la thérapie matricielle.La qualité de notre recherche est reconnue par la Commission Européenne (au travers des instruments SME …See details»
OTR3 - Crunchbase Company Profile & Funding
Organization. OTR3 . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. OTR3 is a biotechnology company. Paris, Ile-de-France, France; 11-50; ... OTR3 is a …See details»
OTR3 - Matrix Therapy Company in Regenerative …
OTR3 is a biotechnology company with a strong focus on the development of matrix therapy. The quality of our research is recognized by the. European Commission (through H2020 SME instruments), by the French National …See details»
French biotech company - OTR3
OTR3 was founded by two well-known biologists: Pr. Denis Barritault and Pr. Jean-Pierre Caruelle. Thanks to their pioneering work on growth factors (FGF, HARP/PTN discovery) and medical and industrial long-term vision, they …See details»
ORGANES TISSUS REGENERATION REPARATION REMPLACEMENT
Présentation de la société ORGANES TISSUS REGENERATION REPARATION REMPLACEMENT (OTR3) ORGANES TISSUS REGENERATION REPARATION …See details»
OTR3 - LinkedIn
OTR3® is a French biotech company that has developed a new class of therapeutic agents used for skin and corneal healing. ... They restore the scaffold organization and the micro …See details»
OTR3 - Products, Competitors, Financials, Employees, …
OTR3 is a clinical-stage biotechnology company focused on regenerative medicine. The company develops matrix therapies using RGTA technology to promote tissue regeneration for patients …See details»
OTR3 - Funding, Financials, Valuation & Investors - Crunchbase
OTR3 is a biotechnology company. Start Free Trial . Chrome ExtensionSee details»
OTR3 - Company Profile & Staff Directory - ContactOut
OTR3® is a French biotech company that has developed a new class of therapeutic agents used for skin and corneal healing. The therapeutic approach, called "Matrix therapy" is based on …See details»
OTR3 Company Profile - Office Locations, Competitors, Revenue
OTR3 is a biotech company that develops a new class of therapeutic agents used for skin, mucosa, and corneal complications. Its therapeutic approach, called Matrix therapy, is based …See details»
OTR3 - Biotechnology - Overview, Competitors, and Employees
They restore the scaffold organization and the micro-environment of the cells allowing the tissue to rebuild. OTR3 has placed on the market medical devices indicated for the treatment of hard …See details»
OTR3 - Contacts, Employees, Board Members, Advisors & Alumni
OTR3 is a biotechnology company. Unlock even more features with Crunchbase ProSee details»
OTR3 Information - RocketReach
They restore the scaffold organization and the micro-environment of the cells allowing the tissue to rebuild. OTR3 has placed on the market medical devices indicated for the treatment of hard …See details»
The OTR3 laboratory | Biotech - RGENtec
OTR3 is a biotech company and a gem of French innovation revolutionizing tissue regeneration. Historically, beyond cosmetics, OTR3 has been a company developing medical devices …See details»
R&D on Regenerating Agents technology - OTR3
Batch release is performed by OTR3 according to the QMS approved by our regulatory agencies. Quality Management System ISO 13485:2016 provides the guidelines for an organization to …See details»
Matrix therapy is a cost-effective solution to reduce amputation …
3 OTR3, SAS, 4 rue Française, 75001 Paris, France 4 CRRET (EA 4397/ERL CNRS 9215), Université Paris-Est, Créteil 94010, France Received 7 October 2019, Accepted 11 November …See details»
Case Reports for Topical Treatment of Corneal Ulcers with a New …
A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Locked padlock icon ) or https:// means you've safely connected …See details»
(PDF) Overview of 10 years of practice with CACIPLIQ20
Background CACIPLIQ20 (OTR3, Paris, France) is a medical device used for the treatment of chronic skin ulcers. It contains a heparan sulfate mimetic which accelerates tissue healing by …See details»
RGTA ® or ReGeneraTing Agents mimic heparan sulfate in
3 OTR3, 4 rue Française, 75001, Paris, France. 4 Laboratory Cell Growth and Tissue Repair (CRRET), UPEC 4397/ERL CNRS 9215, Université Paris Est Cretéil, Université Paris Est, F …See details»
Biotechnology news and events - OTR3
Apr 11, 2023 OTR3 announces first patient enrollment in its pivotal study “MATRISCAR”, a double blind placebo-controlled study aimed at demonstrating the effects of CACIPLIQ20 on …See details»